Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Eisai to Develop Belviq for Japan Market via Expanded Deal with Arena
November 12, 2013
- NCC, Sanofi Forge Alliance in Anticancer Drug R&D
November 12, 2013
- Eisai Enters Global Agreement with Broad Institute of US to Develop New Drugs for NTDs and Tuberculosis
November 12, 2013
- 4 Major Wholesalers’ Operating Margins Stay on Recovery Path, But Average Settlement Rate at Mere 72% at Sept.-End
November 11, 2013
- Nichi-Iko Pres. Airs Frustration with Sanofi over Cancellation of Biosimlar Codevelopment Deal
November 8, 2013
- Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura
November 8, 2013
- Bristol-Myers Files NDA for DCV/ASV Combination Therapy for Treatment of Hepatitis C in Japan
November 8, 2013
- MTPC Aims to Reach Midterm Targets through Royalties from Licensed Products, But Success Likely to Depend on Performance in Domestic Market
November 8, 2013
- Japan ARB Market Gets Back on Growth Track in April-September; No Major Impact from Diovan Woes
November 6, 2013
- Safety Profile Holds Key to Triumph of Edoxaban: Daiichi Sankyo President
November 6, 2013
- Daiichi Sankyo President Apologizes Over Ranbaxy Problem, Pledges to Resolve Issue by Dispatching Employees
November 6, 2013
- Takeda to Cut Costs by 100 Billion Yen, Reduce Workforce by Below 5%
November 5, 2013
- Growth-Engine Drugs Jack Up Eisai Sales in April-September; Aricept’s Japan Target within Sight
November 5, 2013
- Astellas Plans to Tap 300 Workers in Japan for Early Retirement in FY2014
November 5, 2013
- Astellas 1st Half Operating Profit Down 4.4% on Higher Sales
November 5, 2013
- Shionogi Logs Record Profits in April-September on Rigid Cost Control
November 1, 2013
- Daiichi Sankyo Sales Up 7% Thanks to Nexium, Ranbaxy Posts Net Loss
November 1, 2013
- Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen
November 1, 2013
- MTPC Sales of Domestic Ethical Drugs Down 3.2% in April-September Period Due to Generic Competition
October 31, 2013
- DSP North America Sales Up 11.8% Due to Latuda, Japan Sales Down 4.2% in April-September Period
October 31, 2013
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…